Vanda Pharmaceuticals Operating Margin vs. Net Income
| VNDA Stock | USD 8.60 0.32 3.86% |
Vanda Pharmaceuticals Operating Profit Margin |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.7 | 0.9396 |
|
|
For Vanda Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vanda Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vanda Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vanda Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vanda Pharmaceuticals over time as well as its relative position and ranking within its peers.
Vanda Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out World Market Map.
Vanda Pharmaceuticals Revenue Breakdown by Earning Segment
By analyzing Vanda Pharmaceuticals' earnings estimates, investors can diagnose different trends across Vanda Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Vanda Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.96) | Earnings Share (3.74) | Revenue Per Share | Quarterly Revenue Growth 0.076 | Return On Assets |
Understanding Vanda Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Vanda's accounting equity. The concept of intrinsic value - what Vanda Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Vanda Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Vanda Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Vanda Pharmaceuticals Net Income vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Vanda Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Vanda Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Vanda Pharmaceuticals is rated first in operating margin category among its peers. It is rated below average in net income category among its peers . At present, Vanda Pharmaceuticals' Operating Profit Margin is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vanda Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Vanda Net Income vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Vanda Pharmaceuticals |
| = | (0.71) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Vanda Pharmaceuticals |
| = | (220.47 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Vanda Net Income Comparison
Vanda Pharmaceuticals is currently under evaluation in net income category among its peers.
Vanda Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Vanda Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vanda Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Vanda Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Vanda Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 629 K | 660.5 K | |
| Operating Income | -151.2 M | -143.6 M | |
| Income Before Tax | -138.6 M | -131.7 M | |
| Total Other Income Expense Net | 12.5 M | 13.1 M | |
| Net Loss | -220.5 M | -209.5 M | |
| Income Tax Expense | 81.8 M | 85.9 M | |
| Net Income Applicable To Common Shares | 7.2 M | 8.4 M | |
| Net Loss | -220.5 M | -209.5 M | |
| Non Operating Income Net Other | 414.9 K | 368.8 K | |
| Change To Netincome | 22.8 M | 24 M | |
| Net Loss | (3.74) | (3.55) | |
| Income Quality | 0.50 | 0.65 | |
| Net Income Per E B T | 1.59 | 0.88 |
Vanda Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Vanda Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vanda Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vanda Pharmaceuticals' important profitability drivers and their relationship over time.
Vanda Pharmaceuticals Earnings Estimation Breakdown
The calculation of Vanda Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Vanda Pharmaceuticals is estimated to be -0.575 with the future projection ranging from a low of -0.68 to a high of -0.51. Please be aware that this consensus of annual earnings estimates for Vanda Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.68 Lowest | Expected EPS | -0.51 Highest |
Vanda Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Vanda Pharmaceuticals' value are higher than the current market price of the Vanda Pharmaceuticals stock. In this case, investors may conclude that Vanda Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Vanda Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 4 | 22.82% | 0.0 | -0.575 | -3.74 |
Vanda Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Vanda Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Vanda Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Vanda Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Vanda Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Vanda Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Vanda Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Vanda Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Vanda Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2026-02-11 | 2025-12-31 | -0.975 | -2.39 | -1.415 | 145 | ||
2025-11-05 | 2025-09-30 | -0.45 | -0.38 | 0.07 | 15 | ||
2025-07-31 | 2025-06-30 | -0.36 | -0.46 | -0.1 | 27 | ||
2025-05-07 | 2025-03-31 | -0.6 | -0.5 | 0.1 | 16 | ||
2025-02-13 | 2024-12-31 | -0.11 | -0.08 | 0.03 | 27 | ||
2024-11-06 | 2024-09-30 | -0.16 | -0.09 | 0.07 | 43 | ||
2024-07-31 | 2024-06-30 | -0.21 | -0.08 | 0.13 | 61 | ||
2024-05-08 | 2024-03-31 | 0.05 | -0.0718 | -0.1218 | 243 | ||
2024-02-07 | 2023-12-31 | -0.09 | -0.04 | 0.05 | 55 | ||
2023-11-08 | 2023-09-30 | -0.04 | 0.0024 | 0.0424 | 106 | ||
2023-07-27 | 2023-06-30 | -0.13 | 0.03 | 0.16 | 123 | ||
2023-05-03 | 2023-03-31 | 0.06 | 0.06 | 0.0 | 0 | ||
2023-02-08 | 2022-12-31 | 0.08 | 0.12 | 0.04 | 50 | ||
2022-11-02 | 2022-09-30 | 0.09 | 0.06 | -0.03 | 33 | ||
2022-08-03 | 2022-06-30 | 0.11 | 0.05 | -0.06 | 54 | ||
2022-05-05 | 2022-03-31 | -0.01 | -0.11 | -0.1 | 1000 | ||
2022-02-23 | 2021-12-31 | 0.09 | 0.12 | 0.03 | 33 | ||
2021-11-03 | 2021-09-30 | 0.18 | 0.14 | -0.04 | 22 | ||
2021-07-28 | 2021-06-30 | 0.14 | 0.17 | 0.03 | 21 | ||
2021-05-05 | 2021-03-31 | 0.15 | 0.15 | 0.0 | 0 | ||
2021-02-10 | 2020-12-31 | 0.14 | 0.15 | 0.01 | 7 | ||
2020-10-28 | 2020-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-08-05 | 2020-06-30 | 0.04 | 0.16 | 0.12 | 300 | ||
2020-05-06 | 2020-03-31 | 0.08 | 0.01 | -0.07 | 87 | ||
2020-02-25 | 2019-12-31 | 0.11 | 0.08 | -0.03 | 27 | ||
2019-11-06 | 2019-09-30 | 0.07 | 0.22 | 0.15 | 214 | ||
2019-07-31 | 2019-06-30 | 0.04 | 0.21 | 0.17 | 425 | ||
2019-05-01 | 2019-03-31 | 0.06 | -0.01 | -0.07 | 116 | ||
2019-02-13 | 2018-12-31 | 0.01 | 0.19 | 0.18 | 1800 | ||
2018-11-07 | 2018-09-30 | -0.03 | 0.13 | 0.16 | 533 | ||
2018-08-01 | 2018-06-30 | -0.18 | 0.09 | 0.27 | 150 | ||
2018-05-02 | 2018-03-31 | -0.17 | 0.06 | 0.23 | 135 | ||
2018-02-14 | 2017-12-31 | -0.12 | -0.04 | 0.08 | 66 | ||
2017-11-07 | 2017-09-30 | -0.11 | -0.1 | 0.01 | 9 | ||
2017-08-02 | 2017-06-30 | -0.28 | -0.03 | 0.25 | 89 | ||
2017-05-02 | 2017-03-31 | -0.19 | -0.17 | 0.02 | 10 | ||
2017-02-15 | 2016-12-31 | -0.09 | -0.01 | 0.08 | 88 | ||
2016-11-02 | 2016-09-30 | -0.08 | -0.01 | 0.07 | 87 | ||
2016-07-27 | 2016-06-30 | -0.22 | -0.11 | 0.11 | 50 | ||
2016-05-04 | 2016-03-31 | -0.24 | -0.29 | -0.05 | 20 | ||
2016-02-10 | 2015-12-31 | -0.26 | -0.35 | -0.09 | 34 | ||
2015-11-03 | 2015-09-30 | -0.2 | -0.22 | -0.02 | 10 | ||
2015-07-29 | 2015-06-30 | -0.28 | -0.13 | 0.15 | 53 | ||
2015-05-06 | 2015-03-31 | -0.25 | -0.24 | 0.01 | 4 | ||
2015-02-19 | 2014-12-31 | -0.2 | -0.2 | 0.0 | 0 | ||
2014-10-27 | 2014-09-30 | -0.39 | -0.04 | 0.35 | 89 | ||
2014-08-07 | 2014-06-30 | -0.73 | -0.64 | 0.09 | 12 | ||
2014-05-08 | 2014-03-31 | -0.29 | -0.49 | -0.2 | 68 | ||
2014-02-13 | 2013-12-31 | -0.2 | -0.23 | -0.03 | 15 | ||
2013-11-07 | 2013-09-30 | -0.3 | -0.17 | 0.13 | 43 | ||
2013-07-31 | 2013-06-30 | -0.22 | -0.11 | 0.11 | 50 | ||
2013-05-09 | 2013-03-31 | -0.25 | -0.15 | 0.1 | 40 | ||
2013-02-12 | 2012-12-31 | -0.22 | -0.23 | -0.01 | 4 | ||
2012-11-07 | 2012-09-30 | -0.22 | -0.19 | 0.03 | 13 | ||
2012-08-02 | 2012-06-30 | -0.27 | -0.28 | -0.01 | 3 | ||
2012-05-08 | 2012-03-31 | -0.16 | -0.28 | -0.12 | 75 | ||
2012-02-14 | 2011-12-31 | -0.19 | -0.2 | -0.01 | 5 | ||
2011-11-04 | 2011-09-30 | -0.07 | -0.11 | -0.04 | 57 | ||
2011-08-04 | 2011-06-30 | -0.05 | -0.05 | 0.0 | 0 | ||
2011-02-10 | 2010-12-31 | -0.02 | 0.08 | 0.1 | 500 | ||
2010-11-03 | 2010-09-30 | 0.03 | 0.11 | 0.08 | 266 | ||
2010-08-05 | 2010-06-30 | 0.09 | 0.04 | -0.05 | 55 | ||
2010-05-04 | 2010-03-31 | 0.09 | 0.02 | -0.07 | 77 | ||
2010-02-16 | 2009-12-31 | -0.16 | -0.34 | -0.18 | 112 | ||
2009-11-02 | 2009-09-30 | -0.3 | -0.28 | 0.02 | 6 | ||
2009-08-10 | 2009-06-30 | -0.41 | -0.46 | -0.05 | 12 | ||
2009-04-29 | 2009-03-31 | -0.22 | -0.24 | -0.02 | 9 | ||
2009-02-11 | 2008-12-31 | -0.36 | -0.28 | 0.08 | 22 | ||
2008-10-30 | 2008-09-30 | -0.4 | -0.41 | -0.01 | 2 | ||
2008-08-05 | 2008-06-30 | -0.63 | -0.51 | 0.12 | 19 | ||
2008-05-01 | 2008-03-31 | -0.83 | -0.72 | 0.11 | 13 | ||
2008-02-14 | 2007-12-31 | -0.79 | -0.78 | 0.01 | 1 | ||
2007-11-08 | 2007-09-30 | -0.97 | -0.82 | 0.15 | 15 | ||
2007-08-02 | 2007-06-30 | -0.81 | -0.6 | 0.21 | 25 | ||
2007-05-01 | 2007-03-31 | -0.56 | -0.61 | -0.05 | 8 | ||
2007-02-07 | 2006-12-31 | -0.64 | -0.54 | 0.1 | 15 | ||
2006-11-02 | 2006-09-30 | -0.95 | -0.55 | 0.4 | 42 | ||
2006-08-03 | 2006-06-30 | -0.83 | -1.11 | -0.28 | 33 |
Use Vanda Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vanda Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vanda Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Vanda Pharmaceuticals Pair Trading
Vanda Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Vanda Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vanda Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vanda Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vanda Pharmaceuticals to buy it.
The correlation of Vanda Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vanda Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vanda Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vanda Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Vanda Pharmaceuticals position
In addition to having Vanda Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
To fully project Vanda Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Vanda Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Vanda Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.